Jennifer Towne - Vir Biotechnology Executive Officer
| VIR Stock | USD 7.12 0.17 2.45% |
Executive
Jennifer Towne is Executive Officer of Vir Biotechnology
| Address | 1800 Owens Street, San Francisco, CA, United States, 94158 |
| Phone | 415 906 4324 |
| Web | https://www.vir.bio |
Vir Biotechnology Management Efficiency
The company has Return on Asset of (0.1941) % which means that on every $100 spent on assets, it lost $0.1941. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3658) %, meaning that it generated no profit with money invested by stockholders. Vir Biotechnology's management efficiency ratios could be used to measure how well Vir Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/24/2024, Return On Tangible Assets is likely to drop to -0.34. In addition to that, Return On Capital Employed is likely to drop to -0.41. At this time, Vir Biotechnology's Net Tangible Assets are relatively stable compared to the past year. As of 11/24/2024, Non Currrent Assets Other is likely to grow to about 19.8 M, while Non Current Assets Total are likely to drop slightly above 219 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Julian Baker | Blueprint Medicines Corp | 57 | |
| Ram Kamineni | Krystal Biotech | N/A | |
| Mark Underwood | Madrigal Pharmaceuticals | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Ronald Plasterk | CureVac NV | N/A | |
| Emily Hill | PTC Therapeutics | 44 | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| John Karakkal | Krystal Biotech | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Hege SollieZetlmayer | PTC Therapeutics | N/A | |
| Patrick Baumhof | CureVac NV | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Patrick Lamy | Akero Therapeutics | 51 | |
| John Schembri | Akero Therapeutics | 62 | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Ariel Hurley | Blueprint Medicines Corp | 50 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.19 |
Vir Biotechnology Leadership Team
Elected by the shareholders, the Vir Biotechnology's board of directors comprises two types of representatives: Vir Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vir. The board's role is to monitor Vir Biotechnology's management team and ensure that shareholders' interests are well served. Vir Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vir Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Klaus Frueh, CoFounder Advisor | ||
| Vanina JD, General VP | ||
| Lawrence MD, CoFounder Advisor | ||
| Johanna FriedlNaderer, Ex COO | ||
| George Scangos, CEO Pres | ||
| MBA MSc, CEO Director | ||
| Louis MD, CoFounder Advisor | ||
| Ann Hanly, Executive Officer | ||
| Sung Lee, Executive CFO | ||
| Pr MD, SVP Fellow | ||
| Jeff MD, Executive Officer | ||
| Arran Attridge, Senior Communications | ||
| Jennifer Towne, Executive Officer | ||
| MBA EdD, Executive Officer | ||
| Steven Rice, Exec Officer | ||
| Jason OByrne, Executive CFO | ||
| Heather Armstrong, Vice Relations | ||
| Howard Horn, CFO VP | ||
| Phillip MD, Executive Officer | ||
| Cara Miller, Vice Communications | ||
| Brent Sabatini, Principal VP |
Vir Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vir Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (91.85) % | ||||
| Current Valuation | 178.91 M | ||||
| Shares Outstanding | 137.72 M | ||||
| Shares Owned By Insiders | 11.90 % | ||||
| Shares Owned By Institutions | 74.45 % | ||||
| Number Of Shares Shorted | 5.72 M | ||||
| Price To Earning | 3.16 X | ||||
| Price To Book | 0.79 X |
Pair Trading with Vir Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.